Bupropion found to not improve sexual desire for female cancer survivors

10 December 2021

Despite preliminary supporting evidence that the dopaminergic agent bupropion might improve sexual desire for female cancer survivors, the NRG Oncology CC004 clinical trial determined that bupropion did not improve outcomes when compared to a placebo. Though the results of this trial were negative, this study supports the urgent need to find effective treatment solutions for the large population of women who are concerned about side effects to their sexual desire following their cancer therapy. These results were published in the Journal of Clinical Oncology.

NRG-CC004 compared two dose-levels of extended-release bupropion in postmenopausal women who were diagnosed with breast or gynecologic cancer and completed their cancer treatment, but who had low baseline sexual desire scores.
